Pharmachronicles

Top Menu

  • Home
  • Our Blog
  • Contact Us

Main Menu

  • Home Page
  • STUDENTS ZONE
  • Syllabus
  • Seminars & conferences
  • Online classes
    • Register
Sign in / Join

Login

Welcome! Login in to your account
Lost your password?

Lost Password

Back to login
  • Home
  • Our Blog
  • Contact Us

Pharmachronicles

Header Banner

Pharmachronicles

  • Home Page
  • STUDENTS ZONE
  • Syllabus
  • Seminars & conferences
  • Online classes
    • Register
  • UGC-Cancelled-List of journals

  • NAAC stops accepting applications for accreditation from pharmacy colleges

  • Pursuing MPhil/PhD while working as a teacher will effect experience: UGC

  • Public notice by government of india ministry of health and family welfare

FDA Alerts
Home›FDA Alerts›FDA approves a new drug to treat malaria which could help millions.

FDA approves a new drug to treat malaria which could help millions.

By Sriram Nagarajan
July 24, 2018
404
0
Share:

The Food and Drug Administration has approved the drug Krintafel (tafenoquine) for the treatment of malaria following a Priority Review this past Friday.

The drug, developed by GSK Pharmaceuticals and Medicines for Malaria Venture, is a single dose medication designed for people who’ve had malaria before. It prevents the relapse of malaria caused by Plasmodium vivax (P.vivax).

P.vivax is one of several parasites in the Plasmodium family known to cause malaria. It accounts for infection with malaria in 15-20% of the cases around the world; that’s roughly 8.5 million infections per year.

Unlike its cousin Plasmodium falciparum, which is responsible for approximately 75% of the cases, following the initial infection in the blood, P. vivax can go into a dormant stage in the liver, where most anti-malaria medications cannot reach it.

Currently, patients with P.vivax require a 10 day treatment with the drug Primaquine to eradicate those dormant liver parasites. Many patients, much to the frustration of doctors, do not complete all 10 days of treatment, leading to the survival of the parasite and the recurrence of malaria.

Krintafel, approved this past Friday, eradicates dormant P.vivax parasites after one dose.

Dr. David Reddy, Chief Executive Officer of Medicines for Malaria Venture said in a press release, “The US FDA’s approval of Krintafel is a major milestone and a significant contribution towards global efforts to eradicate malaria. The world has waited decades for a new medicine to counter P. vivax malaria relapse. Today, we can say the wait is over. Moreover, as the first ever single-dose for this indication, Krintafel will help improve patient compliance. We are proud to have worked side-by-side with GSK for more than a decade to reach this point. Our focus is now on working to ensure the medicine reaches the vulnerable patients that need it most.”

The efficacy and safety of the drug were established in two large randomized studies published in the summer of 2017. Manufacturers do warn patients with a deficiency in an enzyme in red blood cells known as G6PD, women breastfeeding a child with G6PD deficiency, or anyone who has not been tested for this condition, should not take Krintafel due to the risk for worsening anemia.

In an interview with ABC news, Dr. Regina Rabinovich, President of the American Society of Tropical Medicine and Hygiene (ASTMH) and ExxonMobil Malaria Scholar in Residence at Harvard University, extended her congratulations to the team involved in this effort, because they are “addressing a part of the burden of malaria often neglected by the global agenda. P vivax used to be thought of as benign, but it is not benign.”

So does this medication complete what doctors need in the global efforts against malaria? Dr. Rabinovich says “There is no silver bullet in malaria.” She speaks to the importance of a multi-faceted approach- “We need basic prevention technologies, surveillance and reporting, really good health systems, and surveillance response. You have to be able to do something to help once you identify a problem.”

According to the 2017 report from the World Health Organization, in 2016 there were an estimated 216 million cases of malaria, an increase of about 5 million cases over 2015, warning that previous advances and efforts have stalled.

Dr. Rabinovich worries the 2018 report, which will be released later this year, might be even worse, in part due to decreased global funding for malaria prevention.

 

Tagsfdagskmalaria drugWHO
Previous Article

Pursuing MPhil/PhD while working as a teacher ...

Next Article

“RANIPILL”- A MINI SWALLOWABLE AUTO INJECTOR WITH ...

0
Shares
  • 0
  • +
  • 0
  • 0
  • 0
  • 0

Sriram Nagarajan

Related articles More from author

  • BLOGS

    US FDA approves first biosimilar for certain breast and stomach cancers treatment

    December 4, 2017
    By admin
  • BLOGS

    New malaria drug AQ-13 found effective in human trial

    September 14, 2017
    By admin
  • Trials

    Progression of rare connective tissue tumor controlled by targeted therapy

    December 26, 2018
    By Ramoju kishore kumar
  • FDA Alerts

    FDA Approves Humanized Monoclonal Antibody For Migraine Treatment.

    September 30, 2018
    By Sriram Nagarajan
  • Uncategorized

    India needs 2.07 million of doctors by 2030

    December 7, 2017
    By admin
  • BLOGS

    Treating Hereditary blindness by gene therapy will be a revolution in medical field

    October 20, 2017
    By admin

Leave a reply Cancel reply

You may interested

  • BLOGS

    DUAL CONTROL OF PHARMACY EDUCATION IN INDIA

  • BLOGS

    Non immune engineered cells that can kill cancer cell upon contact

  • BLOGS

    NEW TOOL FOR THE IDENTIFICATION OF MALARIA

  • LATEST REVIEWS

  • TOP REVIEWS

  • Pharmacists are not eligible for certificate program of community health

    0
  • A New Class of Antimicrobials Has Just Been Found in Human Breast Milk Fresh super ...

    0

Timeline

  • October 20, 2020

    List of UGC Approved journals 2020

  • August 8, 2020

    LIST OF SCOPUS INDEXED JOURNALS JUNE 2020

  • June 8, 2020

    Brain Tumor Day -8th June – Endoscopic surgery: An innovative approach to treat brain tumour

  • June 4, 2020

    UGC-Cancelled-List of journals

  • June 1, 2020

    Saroj Group Of Hospitals restarts its complete operations – see major footfall in OPD consultation

Latest Comments

  • ActionScheduler
    on
    March 9, 2020
    action complete

    wc_admin_unsnooze_admin_notes

  • ActionScheduler
    on
    March 9, 2020
    action created

    wc_admin_unsnooze_admin_notes

  • ActionScheduler
    on
    March 9, 2020
    action started

    wc_admin_unsnooze_admin_notes

  • ActionScheduler
    on
    March 9, 2020
    action complete

    wc_admin_unsnooze_admin_notes

  • ActionScheduler
    on
    March 9, 2020
    action created

    wc_admin_unsnooze_admin_notes

Find us on Facebook

Follow Us on Instagram

logo

Dui viverra Faucibus aliquet quis phasellus accumsan. Donec et facilisis sociosqu sed tortor elit eu aliquid turpis ridiculus.

Fly, shall, have greater fifth spirit midst under from stars thing is, had creepeth multiply kind. Man may they’re meat years have third bring replenish air two light deep fill.

About us

  • Dr.N.Sriram, Founder CEO, Pharmachronicles, HITS college of Pharmacy, Ghatkesar, Hyderabad, India
  • 9704361947
  • pharmachronicles@gmail.com
  • Recent

  • Popular

  • Comments

  • List of UGC Approved journals 2020

    By admin
    October 20, 2020
  • LIST OF SCOPUS INDEXED JOURNALS JUNE 2020

    By admin
    August 8, 2020
  • Brain Tumor Day -8th June – Endoscopic surgery: An innovative approach to treat brain tumour

    By Sriram Nagarajan
    June 8, 2020
  • UGC-Cancelled-List of journals

    By admin
    June 4, 2020
  • FDA is carefully evaluating prescription opioid medications approved to treat cough in children

    By admin
    July 16, 2015
  • Record Numbers of FDA‑Approved Drugs: Recent Trends

    By admin
    July 16, 2015
  • There make for Sixth that multiply blessed two divide creeping

    By admin
    July 16, 2015
  • FDA approved new drugs 2017

    By admin
    July 16, 2015
  • ActionScheduler
    on
    March 9, 2020

    wc_admin_unsnooze_admin_notes

    action complete
  • ActionScheduler
    on
    March 9, 2020

    wc_admin_unsnooze_admin_notes

    action created
  • ActionScheduler
    on
    March 9, 2020

    wc_admin_unsnooze_admin_notes

    action started
  • ActionScheduler
    on
    March 9, 2020

    wc_admin_unsnooze_admin_notes

    action complete

Photostream

    Follow us

    • Contact
    • STUDENTS ZONE
    • About Us
    © Copyright Pharmachronicles. All rights reserved.